Trial Profile
A Retrospective study Evaluating Long-Term safety and Efficacy of Mexiletine in Patients With Skeletal Muscle Channelopathies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2015
Price :
$35
*
At a glance
- Drugs Mexiletine (Primary)
- Indications Arrhythmias; Diabetic nephropathies
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2015 Status changed from not stated to completed.
- 22 Dec 2015 New trial record
- 01 Dec 2015 Results published in the JAMA Neurology